Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  Xetra  >  Bayer AG    BAYN   DE000BAY0017


Real-time Estimate Quote. Real-time Estimate Tradegate - 08/14 01:36:19 am
57.74 EUR   +0.21%
08/12GRAIN HIGHLIGHTS : Top Stories of the Day
08/12BAYER : Temasek Form New Company Focused on Vertical Farming
08/12BAYER AG : Goldman Sachs keeps its Buy rating
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Bayer bets on science in bid to prevent future Roundup lawsuits: legal experts

share with twitter share with LinkedIn share with facebook
06/25/2020 | 02:45pm EDT
FILE PHOTO: The historic headquarters of German pharmaceutical and chemical maker Bayer AG is pictured in Leverkusen

By Tina Bellon

Seeking to forestall further claims, Bayer AG is taking a risky bet that an independent scientific review will ultimately show that its widely used weed killer Roundup does not cause cancer, legal experts said.

The company on Wednesday agreed to pay as much as $10.9 billion to end the litigation by U.S. Roundup users who say the herbicide caused them to develop a form of blood cancer.

But Bayer had to find a separate solution to mitigate the risk of future claims without pulling the product off the shelves. The company decided to make a calculated gamble on the scientific evidence which so far has overwhelmingly supported its claim that glyphosate, the active ingredient in Roundup, is safe for agricultural use.

Regulators worldwide, including the U.S. Environmental Protection Agency and the European Chemicals Agency, have determined glyphosate to be non-carcinogenic.

But the World Health Organization's cancer research arm determined the herbicide to be a "probable carcinogen" in 2015 and since 2018, three consecutive U.S. juries, who listened to scientific evidence from both sides during trial, found that Roundup causes cancer.

"Bayer is taking a huge risk by doing this and it's a bet that time can show that the science underlying the plaintiffs' claims is bad," said David Noll, a law professor at Rutgers University.

While many details of the proposal have yet to be released by Bayer and approved by a federal judge, the plan calls for an independent panel of scientific experts, who will likely be chosen and agreed upon by both sides.

The company will pay $1.25 billion to support the panel's research, an amount that does not include any payouts to settle future lawsuits.

The scientific review process is expected to take at least four years, and findings by the panel would be binding on Bayer and anyone who has used Roundup before Wednesday but not developed cancer.

If the panel finds glyphosate to be non-carcinogenic, those users could not sue.

If the panel determines glyphosate causes cancer, however, Bayer could face a flood of new lawsuits, with potential damages determined at a later stage. Bayer on Wednesday said the lead plaintiffs' lawyers have agreed to its plans, but Reuters was not immediately able to reach those attorneys for comment.

Lawyers for Roundup cancer claimants in the past have alleged that Bayer manipulated scientific studies and deceived the scientific community, claims Bayer denies.

Company executives on calls with reporters and analysts on Wednesday repeatedly said the science was in their favor.

"We are confident that the science panel will look at the scientific body of evidence and come to the conclusion that glyphosate is safe," said Bayer's global head of litigation, Bill Dodero.

Scientific panels have been set up in previous mass torts but generally not as part of a settlement process, legal experts said. Bayer's proposal was "creative but risky" and will likely face procedural challenges in court, said Adam Zimmerman, a professor at Loyola Law School.

The experts said many details, including how people who have not yet gotten sick could give up their rights to a future lawsuit under the proposal, remained unclear.


(This story corrects second paragraph to reflect that $10.9 billion is the total settlement amount, not just the amount paid to settle 75% of cases)



(Reporting by Tina Bellon; Editing by Cynthia Osterman)

share with twitter share with LinkedIn share with facebook
All news about BAYER AG
08/12GRAIN HIGHLIGHTS : Top Stories of the Day
08/12BAYER : Temasek Form New Company Focused on Vertical Farming
08/12BAYER AG : Goldman Sachs keeps its Buy rating
08/11NEWS HIGHLIGHTS : Top Company News of the Day
08/11NEWS HIGHLIGHTS : Top Company News of the Day
08/11NEWS HIGHLIGHTS : Top Company News of the Day
08/11BAYER AG : Receives a Buy rating from Deutsche Bank
08/11Bayer takes on Astellas in purchase of experimental menopause relief
08/11BAYER : buys British developer of treatment for menopausal symptoms
08/11BAYER : to Buy KaNDy Therapeutics
More news
Sales 2020 43 562 M 51 443 M 51 443 M
Net income 2020 888 M 1 049 M 1 049 M
Net Debt 2020 32 296 M 38 139 M 38 139 M
P/E ratio 2020 -25,9x
Yield 2020 4,97%
Capitalization 56 607 M 66 959 M 66 849 M
EV / Sales 2020 2,04x
EV / Sales 2021 1,95x
Nbr of Employees 101 168
Free-Float 100,0%
Duration : Period :
Bayer AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BAYER AG
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 26
Average target price 80,81 €
Last Close Price 57,62 €
Spread / Highest target 90,9%
Spread / Average Target 40,2%
Spread / Lowest Target -20,2%
EPS Revisions
Werner Baumann Chairman-Management Board
Norbert Winkeljohann Chairman-Supervisory Board
Wolfgang U. Nickl Chief Financial Officer
Bijoy Sagar Chief Information Technology Officer
Paul Achleitner Member-Supervisory Board
Sector and Competitors
1st jan.Capitalization (M$)
BAYER AG-20.86%66 959
JOHNSON & JOHNSON1.46%394 028
ROCHE HOLDING AG1.08%297 694
PFIZER, INC.-2.58%212 995
MERCK & CO., INC.-8.15%209 118
NOVARTIS AG-15.76%187 147